Please assess the completion status of the following clinical trial:

Trial Title: The Antiseptic Efficacy and Tolerability of Lavasept® 0.04% on Acute Traumatic Wounds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with acute traumatic cut, crush, abrasion, bite or stab wounds Provision of voluntary consent to participate in the study, following a full explanation of the nature and purpose of the study, by signing the informed consent form approved by the Institutional Ethics Committee (IEC) prior to all evaluations~* Wounds that are a minimum of approximately 4 cm2 in size~* Ability to read and understand the German patient information sheet and informed consent form~Exclusion Criteria:~* \< 18 years of age~* Pregnancy~* Immunosuppression~* Wounds caused by a burn~* Wounds that require treatment of hyaline cartilage, the central nervous system, peritoneum, meningae, inner / middle ear or inner eye~* Simultaneous participation in another clinical trial~* Wounds that require immediate surgical or medical treatment as well patients who are critically ill~* Patient with a known allergy to the active agent or any of the excipients~* Wounds that are \>3 cm in depth~* Wounds that have not received medical treatment for ≥6 hours~* Heavily bleeding wounds~* Open fractures, joints or tendons~* Wounds of the face

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ringer's Solution (Type: PLACEBO_COMPARATOR): None
- Lavasept 0.04% (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).